Schedule 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934    

(Amendment No.     )*

 

 

QUOTIENT LIMITED

(Name of Issuer)

Ordinary Shares, no par value

(Title of Class of Securities)

G73268 107

(CUSIP Number)

April 30, 2014

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


13G

 

CUSIP No. G73268 107   Page 1 of 3 Pages

 

  1.   

Names of reporting persons

 

D.J. Paul E. Cowan

  2.  

Check the appropriate box if a member of a group (see instructions)

(a)  ¨        (b)  x

 

  3.  

SEC use only

 

  4.  

Citizenship or place of organization

 

    United Kingdom

Number of

shares

beneficially

owned by

each

reporting

person

with

   5.    

Sole voting power

 

    106,152 Ordinary Shares

   6.   

Shared voting power

 

    3,513,054 Ordinary Shares

   7.   

Sole dispositive power

 

    106,152 Ordinary Shares

   8.   

Shared dispositive power

 

    3,513,054 Ordinary Shares

  9.  

Aggregate amount beneficially owned by each reporting person

 

    3,619,206 Ordinary Shares

10.  

Check if the aggregate amount in Row (9) excludes certain shares (see instructions)    ¨

 

11.  

Percent of class represented by amount in Row (9)

 

    21.3%

12.  

Type of reporting person (see instructions)

 

    IN

 


13G

 

CUSIP No. G73268 107   Page 2 of 3 Pages

 

  1.   

Names of reporting persons

 

Deidre M. Cowan

  2.  

Check the appropriate box if a member of a group (see instructions)

(a)  ¨        (b)  x

 

  3.  

SEC use only

 

  4.  

Citizenship or place of organization

 

    Australia

Number of

shares

beneficially

owned by

each

reporting

person

with

   5.    

Sole voting power

 

    0

   6.   

Shared voting power

 

    3,513,054 Ordinary Shares

   7.   

Sole dispositive power

 

    0

   8.   

Shared dispositive power

 

    3,513,054 Ordinary Shares

  9.  

Aggregate amount beneficially owned by each reporting person

 

    3,513,054 Ordinary Shares

10.  

Check if the aggregate amount in Row (9) excludes certain shares (see instructions)    ¨

 

11.  

Percent of class represented by amount in Row (9)

 

    20.8%

12.  

Type of reporting person (see instructions)

 

    IN

 


13G

 

CUSIP No. G73268 107   Page 3 of 3 Pages

 

  1.   

Names of reporting persons

 

Quotient Biodiagnostics Group Limited (“QBDG”)

  2.  

Check the appropriate box if a member of a group (see instructions)

(a)  ¨        (b)  x

 

  3.  

SEC use only

 

  4.  

Citizenship or place of organization

 

    Jersey, Channel Islands

Number of

shares

beneficially

owned by

each

reporting

person

with

   5.    

Sole voting power

 

    3,513,054 Ordinary Shares

   6.   

Shared voting power

 

    0

   7.   

Sole dispositive power

 

    3,513,054 Ordinary Shares

   8.   

Shared dispositive power

 

    0

  9.  

Aggregate amount beneficially owned by each reporting person

 

    3,513,054 Ordinary Shares

10.  

Check if the aggregate amount in Row (9) excludes certain shares (see instructions)    ¨

 

11.  

Percent of class represented by amount in Row (9)

 

    20.8%

12.  

Type of reporting person (see instructions)

 

    FI

 


Item 1.

 

(a)    Name of Issuer:
  

Quotient Limited (the “Issuer”).

(b)    Address of the Issuer’s Principal Executive Offices:
  

Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 OPZ, United Kingdom.

Item 2.

 

(a)    Name of Person Filing:
   This joint statement on Schedule 13G is being filed by QBDG, Paul Cowan and Deidre Cowan, who are collectively referred to as the “Reporting Persons.”                                                                                                                                  
(b)    Address of Principal Business Office:
   The principal business office of the Reporting Persons with respect to the shares reported hereunder is Elizabeth House, 9 Castle Street, St. Helier Y9 JE2 3RT, Jersey, Channel Islands.                                                                            
(c)    Citizenship:
  

See Item 4 of each cover page.

(d)    Title and Class of Securities:
  

Ordinary Shares, no par value (“Ordinary Shares”).

(e)    CUSIP Number:
  

G73268 107

Item 3.

Not applicable.

Item 4. Ownership:

(a) Amount beneficially owned:

QBDG beneficially owns 3,513,054 Ordinary Shares, which shares QBDG holds directly.

Deidre Cowan, Mr. Cowan’s spouse, beneficially owns 3,513,054 Ordinary Shares, consisting of the 3,513,054 Ordinary Shares held of record by QBDG. Mrs. Cowan is the sole shareholder of QBDG and, in such capacity, exercises sole voting and dispositive power over the shares held of record by QBDG.

Paul Cowan beneficially owns 3,619,206 Ordinary Shares, consisting of (a) 3,513,054 Ordinary Shares beneficially owned by Mr. Cowan’s spouse, Deidre Cowan, who exercises sole voting and dispositive power over the Ordinary Shares held of record by QBDG, (b) 26,666 Ordinary Shares held directly by Mr. Cowan, (c) 59,472 Ordinary Shares Mr. Cowan may acquire upon the exercise of options to purchase Ordinary Shares at $3.29 per Ordinary Share, which options are exercisable as of the date of this filing and (d) 20,014 Ordinary Shares Mr. Cowan may acquire upon the exercise of options to purchase Ordinary Shares at $0.91 per Ordinary Share, which options are exercisable as of the date of this filing. The Ordinary Shares beneficially owned by Mr. Cowan do not include (a) 118,945 Ordinary Shares Mr. Cowan may acquire upon the exercise of options to purchase Ordinary Shares at $3.29 per Ordinary Share, 59,472 of which options will become exercisable on June 28, 2015 and 59,473 of which options will become exercisable on June 28, 2016, and (b) 90,000 Ordinary Shares Mr. Cowan may acquire upon the exercise of options to purchase Ordinary Shares at $8.00 per Ordinary Share, which options will become exercisable in three equal annual instalments beginning April 29, 2015.

The percentage of Ordinary Shares beneficially owned by each Reporting Person is based on a total of 16,916,528 Ordinary Shares of the Issuer outstanding as of February 14, 2015, as reported on the Issuer’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2014.


(b) Percent of class:

See Item 11 of each cover page.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Item 5 of each cover page.

(ii) Shared power to vote or to direct the vote:

See Item 5 of each cover page.

(iii) Sole power to dispose or to direct the disposition of:

See Item 5 of each cover page.

(iv) Shared power to dispose or to direct the disposition of:

See Item 5 of each cover page.

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certifications:

Not applicable.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 12, 2015

 

QUOTIENT BIODIAGNOSTICS GROUP LIMITED
By:

/s/ Deidre M. Cowan

Deidre M. Cowan
Director
PAUL COWAN

/s/ PAUL COWAN

DEIDRE M. COWAN

/s/ DEIDRE M. COWAN


Exhibit Index

 

Exhibit 99.1 Joint Filing Agreement
EX-99.1

Exhibit 99.1

JOINT FILING AGREEMENT

We, Quotient Biodiagnostics Group Limited, Paul Cowan and Deidre M. Cowan, the signatories of the statement on Schedule 13G to which this Joint Filing Agreement is attached, hereby agree that such statement is filed jointly on behalf of Quotient Biodiagnostics Group Limited, Paul Cowan and Deidre M. Cowan. Any subsequent amendments thereto filed by any of us will be filed jointly on behalf of Quotient Biodiagnostics Group Limited, Paul Cowan and Deidre M. Cowan.

Dated: February 12, 2015

 

QUOTIENT BIODIAGNOSTICS GROUP LIMITED
By: /s/ Deidre M. Cowan

Deidre M. Cowan

Director

PAUL COWAN
/s/ PAUL COWAN
DEIDRE M. COWAN
/s/ DEIDRE M. COWAN